U.S., March 21 -- ClinicalTrials.gov registry received information related to the study (NCT06886139) titled 'A Phase 2 Study of TRS005 in Patients with CD20-positive R/R DLBCL.' on March 14.
Brief Summary: This trial is a multicenter, open-label, single-arm, Phase II Study. Patients with CD20 positive recurrent or refractory diffuse large B-cell lymphoma and had failed >=2 prior lines of standard treatment will be recruited. The purpose of this trial is to evaluate the efficacy, safety, pharmacokinetic (PK) and immunogenicity characteristics of TRS005 via intravenous drip.
Study Start Date: July, 2025
Study Type: INTERVENTIONAL
Condition:
CD20-positive Diffuse Large B-Cell Lymphoma
Intervention:
DRUG: TRS005
Recombinant anti-CD20 m...